Published in Behav Brain Res on November 23, 2011
Progress toward treatments for synaptic defects in autism. Nat Med (2013) 1.24
Behavioral phenotypes of genetic mouse models of autism. Genes Brain Behav (2015) 0.96
The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome. Cell Cycle (2015) 0.94
Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back. Neurotherapeutics (2015) 0.90
Modeling fragile X syndrome in the Fmr1 knockout mouse. Intractable Rare Dis Res (2014) 0.88
Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background. Behav Brain Res (2014) 0.87
Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us. Learn Mem (2014) 0.85
Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice. Mol Genet Metab (2014) 0.85
Emerging pharmacologic treatment options for fragile X syndrome. Appl Clin Genet (2015) 0.84
Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes. Front Cell Neurosci (2015) 0.84
Altered nocifensive behavior in animal models of autism spectrum disorder: The role of the nicotinic cholinergic system. Neuropharmacology (2016) 0.83
From FMRP function to potential therapies for fragile X syndrome. Neurochem Res (2013) 0.80
Normal Performance of Fmr1 Mice on a Touchscreen Delayed Nonmatching to Position Working Memory Task. eNeuro (2016) 0.77
Impaired sensorimotor gating in Fmr1 knock out and Fragile X premutation model mice. Behav Brain Res (2014) 0.77
Hyperactive locomotion in a Drosophila model is a functional readout for the synaptic abnormalities underlying fragile X syndrome. Sci Signal (2017) 0.76
FMRP Expression Levels in Mouse Central Nervous System Neurons Determine Behavioral Phenotype. Hum Gene Ther (2016) 0.75
Cell-Type-Specific Translation Profiling Reveals a Novel Strategy for Treating Fragile X Syndrome. Neuron (2017) 0.75
International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev (1998) 5.34
Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell (1994) 4.43
Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology (2005) 4.09
The role of acetylcholine in learning and memory. Curr Opin Neurobiol (2006) 3.49
Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl) (2009) 2.76
Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology (2010) 2.74
Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci (1991) 2.73
Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience (2001) 2.31
Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav (2005) 2.22
The use of behavioral test batteries: effects of training history. Physiol Behav (2001) 2.20
Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome. J Neurosci (2005) 2.19
(Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet (2000) 2.17
Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice. Mol Psychiatry (2004) 2.00
Decreased nociceptive sensitization in mice lacking the fragile X mental retardation protein: role of mGluR1/5 and mTOR. J Neurosci (2007) 1.95
Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A (1999) 1.93
Multiple Gq-coupled receptors converge on a common protein synthesis-dependent long-term depression that is affected in fragile X syndrome mental retardation. J Neurosci (2007) 1.84
Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia (2000) 1.80
Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci (1993) 1.70
Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci (1994) 1.63
Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. Mol Pharmacol (1993) 1.60
FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron (2008) 1.59
A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes Brain Behav (2004) 1.52
Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic-like responses. Autism Res (2011) 1.49
Muscarinic cholinergic influences in memory consolidation. Neurobiol Learn Mem (2003) 1.46
The use of behavioral test batteries, II: effect of test interval. Physiol Behav (2005) 1.39
Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc Natl Acad Sci U S A (1996) 1.39
Characterization of muscarinic M4 binding sites in rabbit lung, chicken heart, and NG108-15 cells. Mol Pharmacol (1990) 1.37
Fmr1 knockout mouse has a distinctive strain-specific learning impairment. Neuroscience (2000) 1.32
Mildly impaired water maze performance in male Fmr1 knockout mice. Neuroscience (1997) 1.32
Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A (2002) 1.25
Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome. Brain Res (2002) 1.25
Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene. Behav Neurosci (2008) 1.21
Self-injurious behavior in young boys with fragile X syndrome. Am J Med Genet A (2003) 1.17
Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol (2002) 1.09
Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry (2003) 1.03
Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice. Brain Res Mol Brain Res (2005) 1.02
Biotinylated m4-toxin demonstrates more M4 muscarinic receptor protein on direct than indirect striatal projection neurons. Brain Res (2001) 1.01
Involvement of cholinergic and gabaergic systems in the fragile X knockout mice. Neuroscience (2003) 0.98
Macroorchidism in FMR1 knockout mice is caused by increased Sertoli cell proliferation during testicular development. Endocrinology (1998) 0.98
Reversal of sensorimotor gating abnormalities in Fmr1 knockout mice carrying a human Fmr1 transgene. Behav Neurosci (2008) 0.97
Self-injurious behavior and fragile X syndrome: findings from the national fragile X survey. Am J Intellect Dev Disabil (2010) 0.96
Modulation of behavioral phenotypes by a muscarinic M1 antagonist in a mouse model of fragile X syndrome. Psychopharmacology (Berl) (2011) 0.96
Development of selective antisera for muscarinic cholinergic receptor subtypes. Ann N Y Acad Sci (1995) 0.95
Prepulse inhibition of acoustic startle in rats after lesions of the pedunculopontine tegmental nucleus. Behav Neurosci (1993) 0.94
Muscarinic receptor subtypes mediating central and peripheral antinociception studied with muscarinic receptor knockout mice: a review. Life Sci (2003) 0.93
Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome. Behav Brain Res (2011) 0.92
Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice. Psychopharmacology (Berl) (2009) 0.90
Effects of anticholinergic drugs selective for muscarinic receptor subtypes on prepulse inhibition in mice. Eur J Pharmacol (2004) 0.88
A prospective clinical analysis of pain behavior and self-injurious behavior. Pain (2005) 0.87
The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide. Behav Neurosci (2011) 0.85
Rat dorsal root ganglia express m1-m4 muscarinic receptor proteins. J Peripher Nerv Syst (1999) 0.82
The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology (Berl) (2007) 0.81
Lesions of the laterodorsal tegmental nucleus disrupt prepulse inhibition of the acoustic startle reflex. Pharmacol Biochem Behav (2004) 0.81
Effects of carbachol on rat Sertoli cell proliferation and muscarinic acetylcholine receptors regulation: an in vitro study. Life Sci (2004) 0.80
Characterization of muscarinic acetylcholine receptor in rat Sertoli cells. Endocrinology (2001) 0.78
Antinociceptive mechanism of the spirocyclopiperazinium compound LXM-10 in mice and rats. Pharmacol Biochem Behav (2010) 0.78
Presence and localization of molecules related to the cholinergic system in developing rat testis. Eur J Histochem (1999) 0.77
Cholinergic inhibition of cAMP accumulation in Sertoli cells cultured from immature hamsters. J Androl (1987) 0.76
Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron (2002) 5.71
Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci (2002) 4.01
Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature (2012) 3.83
Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron (2006) 3.37
A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab (2006) 2.82
Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl) (2009) 2.76
Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome. Hum Mol Genet (2004) 2.61
Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature (2013) 2.49
Engineering GPCR signaling pathways with RASSLs. Nat Methods (2008) 2.29
The nicotinic acetylcholine receptor subunit alpha 5 mediates short-term effects of nicotine in vivo. Mol Pharmacol (2003) 2.00
A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron (2002) 1.97
A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A (2009) 1.90
An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol (2007) 1.83
Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior. Neuron (2008) 1.80
Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res (2003) 1.75
Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med (2012) 1.72
Muscarinic induction of hippocampal gamma oscillations requires coupling of the M1 receptor to two mixed cation currents. Neuron (2002) 1.71
Behavioral and physiological mouse assays for anxiety: a survey in nine mouse strains. Behav Brain Res (2002) 1.68
Multiple residues in the second extracellular loop are critical for M3 muscarinic acetylcholine receptor activation. J Biol Chem (2007) 1.65
A novel experimental strategy to assess the metabolic effects of selective activation of a G(q)-coupled receptor in hepatocytes in vivo. Endocrinology (2013) 1.62
Ectopic expression of CGG containing mRNA is neurotoxic in mammals. Hum Mol Genet (2009) 1.54
M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci (2004) 1.53
Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci (2002) 1.53
Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mice. J Neurosci (2005) 1.52
Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic-like responses. Autism Res (2011) 1.49
Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum. J Neurosci (2010) 1.47
Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice. Naunyn Schmiedebergs Arch Pharmacol (2008) 1.47
Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice. J Neurosci (2002) 1.47
Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in m3 muscarinic acetylcholine receptor-deficient mice. Diabetes (2004) 1.44
Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci (2003) 1.41
Questioning standardization in science. Nat Methods (2009) 1.40
Role of muscarinic receptor subtypes in the constriction of peripheral airways: studies on receptor-deficient mice. Mol Pharmacol (2003) 1.40
The use of behavioral test batteries, II: effect of test interval. Physiol Behav (2005) 1.39
Exaggerated behavioral phenotypes in Fmr1/Fxr2 double knockout mice reveal a functional genetic interaction between Fragile X-related proteins. Hum Mol Genet (2006) 1.38
A mouse model of the human Fragile X syndrome I304N mutation. PLoS Genet (2009) 1.36
Rai1 duplication causes physical and behavioral phenotypes in a mouse model of dup(17)(p11.2p11.2). J Clin Invest (2006) 1.33
Membrane depolarization causes a direct activation of G protein-coupled receptors leading to local Ca2+ release in smooth muscle. Proc Natl Acad Sci U S A (2009) 1.33
Phenotypic characterization of Bbs4 null mice reveals age-dependent penetrance and variable expressivity. Hum Genet (2006) 1.32
Induced chromosome deletions cause hypersociability and other features of Williams-Beuren syndrome in mice. EMBO Mol Med (2009) 1.30
Genetic ablation of M3 muscarinic receptors attenuates murine colon epithelial cell proliferation and neoplasia. Cancer Res (2008) 1.29
Expression of muscarinic and nicotinic acetylcholine receptors in the mouse urothelium. Life Sci (2007) 1.29
Structural basis of G protein-coupled receptor-G protein interactions. Nat Chem Biol (2010) 1.27
Involvement of the alpha3 subunit in central nicotinic binding populations. J Neurosci (2002) 1.26
Role for M5 muscarinic acetylcholine receptors in cocaine addiction. J Neurosci Res (2003) 1.26
RGS4 is a negative regulator of insulin release from pancreatic beta-cells in vitro and in vivo. Proc Natl Acad Sci U S A (2010) 1.25
Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice. Mol Pharmacol (2004) 1.25
Behavioral characterization of mouse models for Smith-Magenis syndrome and dup(17)(p11.2p11.2). Hum Mol Genet (2004) 1.25
Rapid identification of functionally critical amino acids in a G protein-coupled receptor. Nat Methods (2007) 1.24
Loss of M5 muscarinic acetylcholine receptors leads to cerebrovascular and neuronal abnormalities and cognitive deficits in mice. Neurobiol Dis (2006) 1.23
Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease. ACS Chem Neurosci (2012) 1.22
Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene. Behav Neurosci (2008) 1.21
Beneficial metabolic effects of M3 muscarinic acetylcholine receptor deficiency. Cell Metab (2006) 1.21
M(3)-receptor knockout mice: muscarinic receptor function in atria, stomach fundus, urinary bladder, and trachea. Am J Physiol Regul Integr Comp Physiol (2002) 1.21
A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. J Clin Invest (2009) 1.20
Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. Hum Mol Genet (2004) 1.19
Increased sensitivity to nicotine-induced seizures in mice expressing the L250T alpha 7 nicotinic acetylcholine receptor mutation. Mol Pharmacol (2002) 1.18
A Gαs DREADD mouse for selective modulation of cAMP production in striatopallidal neurons. Neuropsychopharmacology (2012) 1.17
Identification of an agonist-induced conformational change occurring adjacent to the ligand-binding pocket of the M(3) muscarinic acetylcholine receptor. J Biol Chem (2005) 1.17
Muscarinic receptor subtype-3 gene ablation and scopolamine butylbromide treatment attenuate small intestinal neoplasia in Apcmin/+ mice. Carcinogenesis (2011) 1.16
Null mutant analysis of responses to nicotine: deletion of beta2 nicotinic acetylcholine receptor subunit but not alpha7 subunit reduces sensitivity to nicotine-induced locomotor depression and hypothermia. Nicotine Tob Res (2004) 1.16
Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor. Mol Pharmacol (2012) 1.16
The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. Proc Natl Acad Sci U S A (2010) 1.15
M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1. Proc Natl Acad Sci U S A (2010) 1.15
Deletion of the beta 2 nicotinic acetylcholine receptor subunit alters development of tolerance to nicotine and eliminates receptor upregulation. Psychopharmacology (Berl) (2005) 1.14
A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors. J Neurosci (2010) 1.14
Chronic activation of a designer G(q)-coupled receptor improves β cell function. J Clin Invest (2013) 1.13
Knockout mouse model for Fxr2: a model for mental retardation. Hum Mol Genet (2002) 1.13
Rai1 deficiency in mice causes learning impairment and motor dysfunction, whereas Rai1 heterozygous mice display minimal behavioral phenotypes. Hum Mol Genet (2007) 1.11
Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol (2002) 1.09
Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. ACS Chem Neurosci (2014) 1.06
Structural basis of M3 muscarinic receptor dimer/oligomer formation. J Biol Chem (2011) 1.06
Deficiency of M2 muscarinic acetylcholine receptors increases susceptibility of ventricular function to chronic adrenergic stress. Am J Physiol Heart Circ Physiol (2007) 1.05
Loss of vagally mediated bradycardia and bronchoconstriction in mice lacking M2 or M3 muscarinic acetylcholine receptors. FASEB J (2004) 1.05
Deletion of the alpha7 nicotinic receptor subunit gene results in increased sensitivity to several behavioral effects produced by alcohol. Alcohol Clin Exp Res (2005) 1.05
M(2) and M(3) muscarinic receptor-mediated contractions in longitudinal smooth muscle of the ileum studied with receptor knockout mice. Br J Pharmacol (2005) 1.05
Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice. Psychopharmacology (Berl) (2007) 1.03
Direct-pathway striatal neurons regulate the retention of decision-making strategies. J Neurosci (2013) 1.03
Conformational changes that occur during M3 muscarinic acetylcholine receptor activation probed by the use of an in situ disulfide cross-linking strategy. J Biol Chem (2001) 1.03
Pitfalls in the interpretation of genetic and pharmacological effects on anxiety-like behaviour in rodents. Behav Pharmacol (2008) 1.03
Hepatic muscarinic acetylcholine receptors are not critically involved in maintaining glucose homeostasis in mice. Diabetes (2009) 1.03
Multiple autism-like behaviors in a novel transgenic mouse model. Behav Brain Res (2010) 1.02
Impaired conditioned fear and enhanced long-term potentiation in Fmr2 knock-out mice. J Neurosci (2002) 1.02
Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands. J Biol Chem (2007) 1.02
M1 muscarinic receptor signaling in mouse hippocampus and cortex. Brain Res (2002) 1.02
Absence of alpha7-containing neuronal nicotinic acetylcholine receptors does not prevent nicotine-induced seizures. Brain Res Mol Brain Res (2002) 1.01
Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J Neurosci (2010) 1.01
Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. Psychopharmacology (Berl) (2011) 1.01
Pronounced conformational changes following agonist activation of the M(3) muscarinic acetylcholine receptor. J Biol Chem (2005) 1.01